Sienna Cancer Diagnostics announced the appointment of Axlab A/S as its exclusive distribution partner for Denmark and Sweden. This distribution agreement, the first to be signed since Sienna's ASX listing, will broaden and accelerate the global roll out of its in-vitro diagnostic (IVD) test. The agreement provides Axlab with the right to sell Sienna's product to pathology laboratories, where it will be used as an adjunct to urine cytology to assist pathologists and urologists in their diagnosis of bladder cancer.